Related Experiment Videos
Lansoprazole versus famotidine in symptomatic reflux esophagitis: a randomized, multicenter study
1Division of Gastroenterology, International Medical Center of Japan, Tokyo.
Journal of Clinical Gastroenterology
|January 1, 1995
Summary
Lansoprazole demonstrated superior effectiveness compared to famotidine in treating moderate to severe reflux esophagitis. Patients receiving lansoprazole initially showed better outcomes and fewer relapses after switching medications.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Gastroesophageal reflux disease (GERD) affects a significant portion of the population.
- Proton pump inhibitors (PPIs) like lansoprazole and H2 receptor antagonists like famotidine are common treatments for reflux esophagitis.
Purpose of the Study:
- To compare the efficacy of lansoprazole and famotidine in treating moderate to severe reflux esophagitis.
- To evaluate patient-reported outcomes and endoscopic findings during treatment.
Main Methods:
- A randomized study involving 54 subjects with moderate to severe reflux esophagitis.
- Two treatment arms: lansoprazole followed by famotidine, and famotidine followed by lansoprazole.
- Evaluations included endoscopic grading and heartburn assessment at baseline, 4 weeks, and 8 weeks.
Main Results:
- Initial improvement rates at 4 weeks were 57.7% for lansoprazole and 38.5% for famotidine, with no significant difference.
- Patients switching to famotidine experienced more condition deterioration than those switching to lansoprazole.
- Lansoprazole was rated "very useful" by 46.2% of patients, significantly higher than famotidine (14.3%).
Conclusions:
- Lansoprazole appears to be a more effective first-line treatment for moderate to severe reflux esophagitis.
- The study suggests a potential benefit of lansoprazole over famotidine in maintaining treatment response.